Review



recombinant human tgfβ1 protein  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 98
      Buy from Supplier

    Structured Review

    MedChemExpress recombinant human tgfβ1 protein
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Recombinant Human Tgfβ1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 293 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgfβ1 protein/product/MedChemExpress
    Average 98 stars, based on 293 article reviews
    recombinant human tgfβ1 protein - by Bioz Stars, 2026-02
    98/100 stars

    Images

    1) Product Images from "GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2"

    Article Title: GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2

    Journal: Cell Communication and Signaling : CCS

    doi: 10.1186/s12964-025-02356-z

    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Figure Legend Snippet: GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)

    Techniques Used: Quantitative RT-PCR, Marker, Expressing, Transfection, Western Blot, Immunofluorescence, Staining, Incubation, Enzyme-linked Immunosorbent Assay

    GPX3-TGFB1 promoted ZEB2 expression and enhanced EMT during cisplatin treatment in TNBC. (A) GEPIA analysis of the relationship between the expression of GPX3, TGFB1, and ZEB2. (B) Correlation analysis of the protein expression levels of GPX3, TGFB1, and ZEB2 in TNBC patient tissue microarrays (n=75). (C-D) Western blot analysis showed that TGFB1 reversed the effect of GPX3 on ZEB2 expression. (E) Existing ChIP-seq analysis of SMAD3 binding sites on the ZEB2 gene promoter (ChiP-Atlas: Enrichment Analysis, https://chip-atlas.org/enrichment_analysis). (F) ChIP-qPCR validation of SMAD3 enrichment at the ZEB2 gene promoter. (G-I) Knocking down SMAD2 or SMAD3 or inhibiting TGFBR1 kinase activity abolished rhTGFβ1-induced transcriptional activity (G), expression level of ZEB2 (H), and EMT markers (I). (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Figure Legend Snippet: GPX3-TGFB1 promoted ZEB2 expression and enhanced EMT during cisplatin treatment in TNBC. (A) GEPIA analysis of the relationship between the expression of GPX3, TGFB1, and ZEB2. (B) Correlation analysis of the protein expression levels of GPX3, TGFB1, and ZEB2 in TNBC patient tissue microarrays (n=75). (C-D) Western blot analysis showed that TGFB1 reversed the effect of GPX3 on ZEB2 expression. (E) Existing ChIP-seq analysis of SMAD3 binding sites on the ZEB2 gene promoter (ChiP-Atlas: Enrichment Analysis, https://chip-atlas.org/enrichment_analysis). (F) ChIP-qPCR validation of SMAD3 enrichment at the ZEB2 gene promoter. (G-I) Knocking down SMAD2 or SMAD3 or inhibiting TGFBR1 kinase activity abolished rhTGFβ1-induced transcriptional activity (G), expression level of ZEB2 (H), and EMT markers (I). (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)

    Techniques Used: Expressing, Western Blot, ChIP-sequencing, Binding Assay, ChIP-qPCR, Biomarker Discovery, Activity Assay



    Similar Products

    recombinant human tgfβ1 protein  (MedChemExpress)
    98
    MedChemExpress recombinant human tgfβ1 protein
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Recombinant Human Tgfβ1 Protein, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgfβ1 protein/product/MedChemExpress
    Average 98 stars, based on 1 article reviews
    recombinant human tgfβ1 protein - by Bioz Stars, 2026-02
    98/100 stars
    		  Buy from Supplier
    human recombinant tgfβ1  (R&D Systems)
    96
    R&D Systems human recombinant tgfβ1
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Human Recombinant Tgfβ1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant tgfβ1/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    human recombinant tgfβ1 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier
    human tgfβ1 recombinant protein  (Thermo Fisher)
    90
    Thermo Fisher human tgfβ1 recombinant protein
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Human Tgfβ1 Recombinant Protein, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human tgfβ1 recombinant protein/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    human tgfβ1 recombinant protein - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    human recombinant tgfβ1 protein  (Yeasen Biotechnology)
    90
    Yeasen Biotechnology human recombinant tgfβ1 protein
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Human Recombinant Tgfβ1 Protein, supplied by Yeasen Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human recombinant tgfβ1 protein/product/Yeasen Biotechnology
    Average 90 stars, based on 1 article reviews
    human recombinant tgfβ1 protein - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    recombinant human tgfβ1 rhtgf β1  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc recombinant human tgfβ1 rhtgf β1
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Recombinant Human Tgfβ1 Rhtgf β1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/recombinant human tgfβ1 rhtgf β1/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    recombinant human tgfβ1 rhtgf β1 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    tgfβ1  (R&D Systems)
    96
    R&D Systems tgfβ1
    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without <t>rhTGFβ1.</t> (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)
    Tgfβ1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tgfβ1/product/R&D Systems
    Average 96 stars, based on 1 article reviews
    tgfβ1 - by Bioz Stars, 2026-02
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)

    Journal: Cell Communication and Signaling : CCS

    Article Title: GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2

    doi: 10.1186/s12964-025-02356-z

    Figure Lengend Snippet: GPX3 enhanced TGF-β1 signaling following cisplatin treatment in MDA-MB-231 cells. (A-B) RT-qPCR analysis of TGFB1 signaling and its EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (C) Western blot analysis of TGFB1 signaling and EMT marker expression levels in cells transfected with NC or GPX3-KD, treated with or without rhTGFβ1. (D-E) Immunofluorescence staining for SMAD2 and SMAD3 in the nuclear and cytoplasmic compartments of NC and GPX3-KD cells treated with rhTGFβ1, with corresponding quantification. (F) Western blot analysis of the ratio of phosphorylated SMAD2/3 (p-SMAD2/3) to total SMAD2 and SMAD3 in NC and GPX3-KD cells treated with rhTGFβ1. (G-H) Secretion levels of total and active TGFB1 in the supernatants of GPX3-KD cells incubated with cisplatin, with or without NAC pre-treatment, as detected by Western blot and ELISA. (I) Western blot analysis of TGF-β signaling and EMT marker expression in GPX3-KD cells, with or without NAC pre-treatment. (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)

    Article Snippet: Cisplatin (Cat. No. HY-17394), SB431542 (TGF-β receptor kinase inhibitors, TRKI, HY-10431), and recombinant human TGFβ1 protein from HEK293 (Cat. No. HY- P70543 ) were purchased from MedChemExpress (MCE).

    Techniques: Quantitative RT-PCR, Marker, Expressing, Transfection, Western Blot, Immunofluorescence, Staining, Incubation, Enzyme-linked Immunosorbent Assay

    GPX3-TGFB1 promoted ZEB2 expression and enhanced EMT during cisplatin treatment in TNBC. (A) GEPIA analysis of the relationship between the expression of GPX3, TGFB1, and ZEB2. (B) Correlation analysis of the protein expression levels of GPX3, TGFB1, and ZEB2 in TNBC patient tissue microarrays (n=75). (C-D) Western blot analysis showed that TGFB1 reversed the effect of GPX3 on ZEB2 expression. (E) Existing ChIP-seq analysis of SMAD3 binding sites on the ZEB2 gene promoter (ChiP-Atlas: Enrichment Analysis, https://chip-atlas.org/enrichment_analysis). (F) ChIP-qPCR validation of SMAD3 enrichment at the ZEB2 gene promoter. (G-I) Knocking down SMAD2 or SMAD3 or inhibiting TGFBR1 kinase activity abolished rhTGFβ1-induced transcriptional activity (G), expression level of ZEB2 (H), and EMT markers (I). (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)

    Journal: Cell Communication and Signaling : CCS

    Article Title: GPX3 promotes cisplatin resistance in TNBC by manipulating ROS-TGFB1-ZEB2

    doi: 10.1186/s12964-025-02356-z

    Figure Lengend Snippet: GPX3-TGFB1 promoted ZEB2 expression and enhanced EMT during cisplatin treatment in TNBC. (A) GEPIA analysis of the relationship between the expression of GPX3, TGFB1, and ZEB2. (B) Correlation analysis of the protein expression levels of GPX3, TGFB1, and ZEB2 in TNBC patient tissue microarrays (n=75). (C-D) Western blot analysis showed that TGFB1 reversed the effect of GPX3 on ZEB2 expression. (E) Existing ChIP-seq analysis of SMAD3 binding sites on the ZEB2 gene promoter (ChiP-Atlas: Enrichment Analysis, https://chip-atlas.org/enrichment_analysis). (F) ChIP-qPCR validation of SMAD3 enrichment at the ZEB2 gene promoter. (G-I) Knocking down SMAD2 or SMAD3 or inhibiting TGFBR1 kinase activity abolished rhTGFβ1-induced transcriptional activity (G), expression level of ZEB2 (H), and EMT markers (I). (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001)

    Article Snippet: Cisplatin (Cat. No. HY-17394), SB431542 (TGF-β receptor kinase inhibitors, TRKI, HY-10431), and recombinant human TGFβ1 protein from HEK293 (Cat. No. HY- P70543 ) were purchased from MedChemExpress (MCE).

    Techniques: Expressing, Western Blot, ChIP-sequencing, Binding Assay, ChIP-qPCR, Biomarker Discovery, Activity Assay